StockData
ArriVent BioPharma, Inc. logo

ArriVent BioPharma, Inc. (AVBP) stock

AVBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$10.69−0.87 (-7.53%)

Close on Nov 17, 2026Market cap $527.10MP/E –Yield –

ArriVent BioPharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

ArriVent BioPharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$147.93M. For fiscal 2025 it was -$160.59M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$160.59M–
FY2024Dec 31, 2024-$70.21M–
FY2023Dec 31, 2023-$55.84M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$39.58M–
Q1 FY2026Mar 31, 2026-$41.89M–
Q4 FY2025Dec 31, 2025-$30.66M–
Q3 FY2025Sep 30, 2025-$35.80M–
Q2 FY2025Jun 30, 2025-$26.12M–
Q1 FY2025Mar 31, 2025-$68.01M–
Q4 FY2024Dec 31, 2024-$16.15M–
Q3 FY2024Sep 30, 2024-$16.35M–
Q2 FY2024Jun 30, 2024-$19.09M–
Q1 FY2024Mar 31, 2024-$18.63M–
Q4 FY2023Dec 31, 2023-$14.91M–
Q3 FY2023Sep 30, 2023-$15.44M–
Q2 FY2023Jun 30, 2023-$8.61M–
Q1 FY2023Mar 31, 2023-$16.88M–

More ArriVent BioPharma figures

See a number that looks wrong?